Neogenomics Inc

Research Neogenomics Inc (NEO) on Bullrun: market cap USD 2.15B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.15B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 727.33M-USD 108.00M-USD 21.78M43.2%-0.84USD 159.62MUSD 341.86MUSD 836.56M
FY2024USD 660.57M-USD 79.00M-USD 34.04M43.9%-0.62USD 367.01MUSD 541.11MUSD 902.34M
FY2023USD 591.64M-USD 88.00M-USD 30.71M41.3%-1.29USD 342.49MUSD 538.20MUSD 941.54M
FY2022USD 509.73M-USD 144.00M-USD 96.88M36.9%n/aUSD 263.18MUSD 611.90MUSD 998.02M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.15Bn/an/an/a
20252025-12-31USD 1.52Bn/an/an/a
20242024-12-31USD 2.11Bn/an/an/a
20232023-12-29USD 2.06Bn/an/an/a
20222022-12-30USD 1.17Bn/an/an/a
20212021-12-31USD 4.23Bn/an/an/a

About Neogenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Neogenomics Inc's market cap?

Neogenomics Inc's market capitalization is USD 2.15B.

What does Neogenomics Inc do?

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.